PRIOR AUTHORIZATION CRITERIA

DRUG CLASS

ANTICONVULSANTS

BRAND NAME (generic)

ONFI (clobazam)

Status: CVS Caremark Criteria Type: Initial Prior Authorization

POLICY

FDA-APPROVED INDICATIONS

Onfi (clobazam) is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

• The requested drug is being prescribed for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in a patient 2 years of age or older

REFERENCES

- 1. Onfi [package insert]. Deerfield, IL: Lundbeck Inc.; December 2016.
- 2. Micromedex Solutions [database online]. Greenwood Village, CO: Truven Health Analytics Inc. Updated periodically. www.micromedexsolutions.com [available with subscription]. Accessed May 2018.
- 3. AHFS DI (Adult and Pediatric) [database online]. Hudson, OH: Lexi-Comp, Inc.; http://online.lexi.com/lco/action/index/dataset/complete_ashp [available with subscription]. Accessed May 2018.

©2018 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.